Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 20/20 | 0.99 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 0.99 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.62 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.62 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.62 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.62 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.62 |
| ▸ | OXTR | P30559 | 10/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5428661 | 1.00 | AVPR1A (0.99) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL31737367 | 0.99 | AVPR1A (1.00) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2598091 | 0.99 | AVPR1A (1.00) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4837407 | 0.94 | AVPR1A (0.90) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL38380 | 0.93 | AVPR1A (0.88) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL6024670 | 0.92 | AVPR1A (0.86) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4695457 | 0.92 | AVPR1A (0.86) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4835403 | 0.91 | AVPR1A (0.85) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4697703 | 0.91 | AVPR1A (0.85) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4835384 | 0.90 | AVPR1A (0.83) | AVPR1AOXTRAVPR2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313106-B1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2025-01-15 | — | — | EP | claimed |
| US-20240197813-A1 | TREATMENT OF DYSPHAGIA | CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (FR) | 2024-06-20 | — | — | US | claimed |
| WO-2022200568-A1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2022-09-29 | — | — | WO | claimed |
| US-20250213544-A1 | ALK5 INHIBITORS AS SKELETAL MUSCLE HYPERTROPHY INDUCERS | CYTOO (FR) | 2025-07-03 | — | — | US | disclosed |
| US-12303498-B2 | ALK5 inhibitors as skeletal muscle hypertrophy inducers | CYTOO (FR) | 2025-05-20 | — | — | US | disclosed |
| WO-2025079436-A1 | DERMAL PAPILLA CELL ACTIVATION COMPOSITION | 国立大学法人横浜国立大学 | 2025-04-17 | — | — | WO | disclosed |
| EP-4313106-B1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2025-01-15 | — | — | EP | disclosed |
| CN-111867632-B | ALK5 inhibitors as skeletal muscle hypertrophy inducers | 赛途公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240240179-A1 | THERAPY FOR TREATMENT OF PRADER-WILLI SYNDROME | THE GENERAL HOSPITAL CORPORATION | 2024-07-18 | — | — | US | disclosed |
| US-20240197813-A1 | TREATMENT OF DYSPHAGIA | CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (FR) | 2024-06-20 | — | — | US | disclosed |
| US-20240010984-A1 | SERUM-FREE MEDIUM FOR DIFFERENTIATION OF A PROGENITOR CELL | Mosa Meat B.V. (NL) | 2024-01-11 | — | — | US | disclosed |
| EP-4251740-A1 | SERUM-FREE MEDIUM FOR DIFFERENTIATION OF A PROGENITOR CELL | Mosa Meat B.V. (NL) | 2023-10-04 | — | — | EP | disclosed |
| CN-116685676-A | Serum-free medium for progenitor cell differentiation | 莫萨米特有限公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023003471-A1 | METHOD FOR PRODUCING CULTURED FAT FOR ANIMAL CONSUMPTION. | Mosa Meat B.V. (NL) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022236296-A1 | THERAPY FOR TREATMENT OF PRADER-WILLI SYNDROME | THE GENERAL HOSPITAL CORPORATION (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022200568-A1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022114955-A1 | SERUM-FREE MEDIUM FOR DIFFERENTIATION OF A PROGENITOR CELL | Mosa Meat B.V. (NL) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303498-B2 | ALK5 inhibitors as skeletal muscle hypertrophy inducers | MUSK, MSTN, ACVRL1 | AVPR1A 3907/4885AVPR2 4223/4885CHRM2 1142/4885 |
| US-20240197813-A1 | TREATMENT OF DYSPHAGIA | OXTR, GRPR, NTSR2 | AVPR1A 22/4885AVPR2 14/4885CHRM2 369/4885 |
| US-20250213544-A1 | ALK5 INHIBITORS AS SKELETAL MUSCLE HYPERTROPHY INDUCERS | MUSK, MSTN, ACVRL1 | AVPR1A 3907/4885AVPR2 4223/4885CHRM2 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.